Oncology

Clinical trials announced for inhaled cancer pain medication

Published in Medical Letter on the CDC and FDA, November 28th, 2004

LAB International announced that it would initiate a Phase II clinical trial in the fourth quarter of 2004 for its lead product, Fentanyl Taifun, an immediate-acting formulation for the treatment of breakthrough cancer pain.

LAB said that successful pre-IND meetings with both U.S. and European regulatory bodies resulted in a development program applicable for both territories, thus enabling expedient further development of the product.

According to the announcement, the Phase II trial will be a multi-center trial in several European countries. The primary objective is to demonstrate the clinical efficacy of Fentanyl Taifun in patients with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry